NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/09/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization4.28 mln
Float3.11 mln
Earnings Date11/05/2026
Piotroski F-Score
4
/ 9
Borderline
1-Year Forecast
14.00
Transformational upside
Relative Strength
4
/ 100
Severely lagging
Debt / Equity
0.00
Debt-free
ROE
-369
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Cadrenal Therapeutics is a Florida-based pharmaceutical company working to bring a new blood-thinning medication called Tecarfarin to patients with serious heart and circulatory conditions. Unlike many existing treatments, Tecarfarin is taken by mouth and can be reversed if needed, making it a promising option for people living with mechanical heart pumps, advanced kidney disease, or conditions that cause dangerous blood clotting. The company has partnered with Abbott Global Enterprises to study how well Tecarfarin works in patients who rely on mechanical heart pump devices.
